Form 4: Vanda Pharmaceuticals CEO Polymeropoulos Increases Stake in Company
SEC Form 4 Filing
Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals, reports acquiring additional shares of common stock.
Summary
- On May 21, 2025, Mihael Hristos Polymeropoulos, the President and CEO of Vanda Pharmaceuticals, acquired 9,519 shares of common stock at a price of $4.4 per share.
- He also acquired 481 shares at $4.39 per share.
- Following these transactions, Polymeropoulos directly owns 2,325,731 shares of Vanda Pharmaceuticals' common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares suggests confidence, but it's a routine transaction.
Positives
- The CEO's purchase of additional shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by investors as it can provide insights into management's perspective on the company's valuation and future performance. It is a common practice for executives to buy or sell shares of their own company, but these transactions must be reported to the SEC.
Stakeholder Impact
- The increased stake of the CEO could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of the stock acquisitions by Mihael Hristos Polymeropoulos |
Keywords
Vanda Pharmaceuticals, Polymeropoulos, insider trading, stock acquisition, Form 4, VNDA, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.